RXRX · Recursion Pharmaceuticals, Inc.
$3.34
-0.17 (-4.71%)
At close · Aug 20
Market Cap
$1.78B
Shares
535.34M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.50
Open$3.28
Day$3.19–3.50
52W close$2.84–6.79
Avg vol 30d18.0M
Short int180.8M · 33.8% float · 9.3d
Short vol51%
Last earningsAug 5, 2026
DataApr 2021–Aug 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Nov 5, 2026
Est · unconfirmed
· in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 5, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−6%
below
Price vs 50-day avg
+7%
above
RSI (14)
60
neutral
MACD trend
Positive
52-week position
17%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+17%
trailing
6-month return
−7%
trailing
YTD return
−14%
this year
Relative strength
−19%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
+1% holders QoQ · +52 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
33.77% of float · ▲ +0.0% MoM · 9.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
345 holders — near 3-yr high, broad support
Squeeze score
82
high risk · 0–100
Fundamentals
Revenue growth
+27%
Y/Y
EPS growth
+15%
Y/Y
Free cash flow
$-378.3M
Balance sheet
$733.7M
net cash
Quant / Vol
risk profile
Volatility
71%
annualized · 1-yr
Max drawdown
−58%
past year
ATR
5.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 6, 2026
Operational cash burn
· 2026
$0 – $390M
Prior guidance
period ended
· from the Earnings Call filed Sep 30, 2025
Expense base
· 2025
up to $450M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−6%
Bearish
Price vs 50-day avg
+7%
Bullish
RSI (14)
60
Neutral
MACD trend
Positive
Bullish
52-week position
17%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
+1% holders QoQ · +52 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
33.77% of float · ▲ +0.0% MoM · 9.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
345 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $3
Now $4 · 17%
Range high $7
vs 200-day avg -6%
vs 50-day avg +7%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| 2026 cash operating expense guidance non-GAAP | $375M | FY 2026 | — |
| Cash Operating Expense non-GAAP | 191M | six months ended June 30, 2026 | — |
| cash, cash equivalents and restricted cash | $556.8M | as of June 30, 2026 | — |
| compounds synthesized from first novel hit to REC-7735 | 242 | fiscal year ended December 31, 2025 | — |
| novel compounds synthesized to identify REC-617 (CDK7) lead candidate | 136 | fiscal year ended December 31, 2025 | — |
| Operating cash expense - 2025 non-GAAP | $399.2M | fiscal year ended December 31, 2025 | — |
| potential total AI-designed small molecule programs under Sanofi collaboration | 15 | fiscal year ended December 31, 2025 | — |
| REC-4881 (4 mg QD) median reduction from baseline at week 25 | 53% | fiscal year ended December 31, 2025 | — |
| REC-4881 (4 mg QD) median reduction in total polyp burden after 12 weeks | 43% | fiscal year ended December 31, 2025 | — |
| upfront and progress-based milestones from Sanofi partnership to date | $134M | fiscal year ended December 31, 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RXRX
this stock
Recursion Pharmaceuticals, Inc.
|
$1.78B | -14.4% | +26.9% | — | 33.8% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +24.0% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +21.8% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +8.9% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +491.3% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RXRX | +6.4% | +17.5% | -7.2% | +16.7% | -14.4% |
| SPY | -0.4% | +2.9% | +11.6% | +3.0% | +12.8% |
| vs SPY | +6.8% | +14.6% | -18.7% | +13.7% | -27.2% |
Key facts
CIK
1601830
CUSIP
75629V104
13F (30d)
318 filings
310 filers
Visit website
Investor relations